Retatrutide is an investigational injectable being developed as a treatment for obesity and type 2 diabetes. It has not completed the approval process, which makes it an unusual subject for a research round-up: almost everything documented about it in public reporting right now concerns supply chains rather than outcomes.

An investigational drug with no legal supply

The Partnership for Safe Medicines, reviewing May and June 2026 pharmaceutical import records, states that retatrutide remains in clinical trials with Eli Lilly, is not FDA-approved, and has no legitimate commercial supply chain for patients. Anything sold outside authorized trials, the group says, comes from the black market.

The scale in the freight data

The same review examined 167 peptide shipments and found that 23% originated from facilities identified as illegitimate manufacturers, while 4% were refused entry. Eight of those shipments were retatrutide, and one alone declared 222,930 pieces.

How the packages are described

Vagueness is doing a lot of work here: 74 of the 167 peptide shipments were labeled only as "peptide" or "custom peptide." In a Fox News opinion piece, former acting Homeland Security secretary Chad Wolf writes that some vendors use coded names such as "GLP-3 RT" and stamp packages "for research use only" while supplying dosing instructions and syringes. He also cites a Customs and Border Protection operation in Cincinnati that uncovered more than 300 master cartons from China containing roughly 5,000 individual peptide shipments, with retatrutide among the seized material.

What patient-safety advocates are warning about

Shabbir Imber Safdar of the Partnership for Safe Medicines, interviewed by FOX 10 Phoenix, argues that buying unapproved GLP-1s and black-market retatrutide online turns consumers into human "lab rats," and that even licensed compounding pharmacies carry safety trade-offs against FDA-approved medicines.

What Isn't Established

None of these sources reports a clinical result for retatrutide: no trial data, no efficacy figure, no safety outcome from the Lilly program appears in any of them. What a buyer is actually injecting is also unestablished, since PSM notes there is no verified manufacturing standard, dose consistency or quality testing outside the approved system.

Where the evidence sits

The public record on retatrutide is currently a regulatory and enforcement record, not a scientific one. The trials are running; the shipments are arriving first.